The effect of implantable cardioverter defibrillator in patients with cardiac resynchronizational therapy and diabetes mellitus

R. Masszi, E. Merkel, W. Schwertner, B. Veres, A. Behon, A. Pintér, I. Osztheimer, E. Zima, L. Gellér, D. Becker, A. Kosztin, B. Merkely
{"title":"The effect of implantable cardioverter defibrillator in patients with cardiac resynchronizational therapy and diabetes mellitus","authors":"R. Masszi, E. Merkel, W. Schwertner, B. Veres, A. Behon, A. Pintér, I. Osztheimer, E. Zima, L. Gellér, D. Becker, A. Kosztin, B. Merkely","doi":"10.1093/europace/euac053.494","DOIUrl":null,"url":null,"abstract":"\n \n \n Type of funding sources: Public grant(s) – National budget only. Main funding source(s): (NKFIA; NVKP_16-1-2016-0017 National Heart Program).\n \n \n \n Heart failure (HF) and diabetes mellitus (DM) are common causes of death on their own, but the coexistance of these two diseases are especially fatal. 1 In DM, sudden cardiac death (SCD) is more common than in non-DM patients, however in many cases, implantable cardioverter defibrillator (ICD) could not prevent SCD. 2\n \n \n \n Our aim is to decide which device warrant higher life expectancy, cardiac resynchronizational therapy with or without defibrillator.\n \n \n \n We examined retrospectively 2525 CRT implanted patients, with a mean follow-up time of 4.6 years. Implantaions were based on the current guidelines. The primary endpoint was all-cause mortality, while our composite end-point were all-cause mortality and heart failure hospitalization.\n \n \n \n In our population, 928 people (36%) had diabetes. We did not find statistical differences between age (68 vs. 68 years; p<0.099), gender (26% women, 23% women; p<0.08) LVEF (28% vs. 29% p<0.1425), incidence of atrial fibrillation (37% vs. 38%; p<0.76), implantation of an ICD (53% vs. 54%; p<0.847), NT-proBNP median levels (2939 pg/ml vs. 2778 pg/ml; p<0.35), and NYHA I (0,5% vs. 0,5%; p<0.898), and NYHA IV stadium (11% vs. 11%; p<0,82). However DM patients had higher BMI (28 kg/m2 vs. 26 kg/m2; p<0.001), lower eGFR levels (57 ml/min/1,73m2 vs. 60 ml/min/1,73m2; p<0.011) higher prevalence of hypertonia (82% vs. 66%; p<0.001), NYHA III stadium (39% vs. 33%; p<0,0008), ischemic etiology (56% vs. 44%; p<0.001), previous acute myocardial infartion (42,9% vs. 36%; p<0.001), a percutan coronaria intervention (35% vs. 25%; p<0.001) compared to non-DM patients. Those patients with DM showed a 25% higher risk of all-cause mortality (HR 1.25; 95% CI 1.12-1.40; p‹0.01) then non-DM patientes, also observable after adjusting for relevant clinical covariates such as age, gender, atrial fibrillation and the addition of an ICD (HR 1.17; 95% CI 1.06-1.31; p‹0.01).\n \n \n \n Adding an ICD for CRT patients with diabetes reduces the risk of all-cause mortality significantly by 32% (HR 0,68; CI 0,56-0,82; p‹0.001) during the first six years but diminished on longer follow-up time (HR 0,95; CI 0,80-1,12; p=0,54).\n","PeriodicalId":11720,"journal":{"name":"EP Europace","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EP Europace","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/europace/euac053.494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): (NKFIA; NVKP_16-1-2016-0017 National Heart Program). Heart failure (HF) and diabetes mellitus (DM) are common causes of death on their own, but the coexistance of these two diseases are especially fatal. 1 In DM, sudden cardiac death (SCD) is more common than in non-DM patients, however in many cases, implantable cardioverter defibrillator (ICD) could not prevent SCD. 2 Our aim is to decide which device warrant higher life expectancy, cardiac resynchronizational therapy with or without defibrillator. We examined retrospectively 2525 CRT implanted patients, with a mean follow-up time of 4.6 years. Implantaions were based on the current guidelines. The primary endpoint was all-cause mortality, while our composite end-point were all-cause mortality and heart failure hospitalization. In our population, 928 people (36%) had diabetes. We did not find statistical differences between age (68 vs. 68 years; p<0.099), gender (26% women, 23% women; p<0.08) LVEF (28% vs. 29% p<0.1425), incidence of atrial fibrillation (37% vs. 38%; p<0.76), implantation of an ICD (53% vs. 54%; p<0.847), NT-proBNP median levels (2939 pg/ml vs. 2778 pg/ml; p<0.35), and NYHA I (0,5% vs. 0,5%; p<0.898), and NYHA IV stadium (11% vs. 11%; p<0,82). However DM patients had higher BMI (28 kg/m2 vs. 26 kg/m2; p<0.001), lower eGFR levels (57 ml/min/1,73m2 vs. 60 ml/min/1,73m2; p<0.011) higher prevalence of hypertonia (82% vs. 66%; p<0.001), NYHA III stadium (39% vs. 33%; p<0,0008), ischemic etiology (56% vs. 44%; p<0.001), previous acute myocardial infartion (42,9% vs. 36%; p<0.001), a percutan coronaria intervention (35% vs. 25%; p<0.001) compared to non-DM patients. Those patients with DM showed a 25% higher risk of all-cause mortality (HR 1.25; 95% CI 1.12-1.40; p‹0.01) then non-DM patientes, also observable after adjusting for relevant clinical covariates such as age, gender, atrial fibrillation and the addition of an ICD (HR 1.17; 95% CI 1.06-1.31; p‹0.01). Adding an ICD for CRT patients with diabetes reduces the risk of all-cause mortality significantly by 32% (HR 0,68; CI 0,56-0,82; p‹0.001) during the first six years but diminished on longer follow-up time (HR 0,95; CI 0,80-1,12; p=0,54).
植入式心律转复除颤器在心脏再同步治疗合并糖尿病患者中的应用效果
资金来源类型:公共拨款-仅限国家预算。主要资金来源:(NKFIA;国家心脏项目(NVKP_16-1-2016-0017)。心衰(HF)和糖尿病(DM)是单独死亡的常见原因,但这两种疾病的共存尤其致命。1在糖尿病患者中,心源性猝死(SCD)比非糖尿病患者更常见,但在许多情况下,植入式心律转复除颤器(ICD)不能预防SCD。我们的目标是确定哪种设备可以保证更高的预期寿命,心脏再同步治疗有或没有除颤器。我们回顾性研究了2525例植入CRT的患者,平均随访时间为4.6年。植入是基于现行的指导方针。主要终点是全因死亡率,而我们的复合终点是全因死亡率和心力衰竭住院。在我们的人群中,928人(36%)患有糖尿病。我们没有发现年龄之间的统计学差异(68岁vs. 68岁;P <0.099),性别(女性26%,女性23%;LVEF (28% vs. 29% p<0.1425)、房颤发生率(37% vs. 38%;p<0.76),植入ICD (53% vs. 54%;p<0.847), NT-proBNP中位水平(2939 pg/ml vs 2778 pg/ml;p<0.35), NYHA I (0,5% vs. 0,5%;p<0.898), NYHA IV体育场(11% vs. 11%;p < 0, 82)。然而,糖尿病患者的BMI更高(28 kg/m2 vs. 26 kg/m2;p<0.001), eGFR水平较低(57 ml/min/1,73m2 vs. 60 ml/min/1,73m2;P <0.011)高渗症的患病率更高(82% vs 66%;p<0.001), NYHA III体育场(39%对33%;P < 0008),缺血性病因(56% vs. 44%;P <0.001),既往急性心肌梗死(42.9% vs. 36%;P <0.001),经皮冠状病毒干预(35% vs. 25%;p<0.001)。糖尿病患者的全因死亡率高出25% (HR 1.25;95% ci 1.12-1.40;p < 0.01),然后是非糖尿病患者,在调整相关临床协变量(如年龄、性别、心房颤动和添加ICD)后也可以观察到(HR 1.17;95% ci 1.06-1.31;p喜爱0.01)。对合并糖尿病的CRT患者增加ICD可显著降低32%的全因死亡风险(HR 0.68;CI 0 56-0 82;p < 0.001),但随着随访时间的延长而减少(HR 0.95;CI 0, 80 - 1, 12;p = 0, 54)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信